STOCK TITAN

Bioventus Inc - BVS STOCK NEWS

Welcome to our dedicated news page for Bioventus (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioventus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioventus's position in the market.

Rhea-AI Summary
Bioventus Inc. (Nasdaq: BVS) reports accelerated fourth-quarter sales growth of 7.6% with organic growth of 14.3%. The company appointed Rob Claypoole as President and CEO, providing full-year 2024 financial guidance. Fourth-quarter 2023 revenue was $135.4 million, a 7.6% increase year-over-year. Full-year 2023 revenue was $512.3 million, with a net loss of $121.2 million. Bioventus aims for net sales of $520-535 million and adjusted EBITDA of $89-94 million for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
-
Rhea-AI Summary
Bioventus Inc. (BVS) will announce Q4 fiscal year 2024 financial results on March 12, 2024. A conference call will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
-
Rhea-AI Summary
Bioventus Inc. (BVS) announced an Amendment to the Credit and Guaranty Agreement, providing financial covenant relief through the Third Quarter of 2025, allowing greater financial and operational flexibility for key growth initiatives and profitability enhancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
Rhea-AI Summary
Bioventus Inc. (Nasdaq: BVS) issued inducement equity awards to Robert Claypoole as President and CEO, consisting of 375,000 restricted share units and options to purchase 850,000 shares of the Company's Class A common stock. The awards will vest in four equal installments on the first four anniversaries of January 10, 2024, subject to continued employment. The exercise price for the options is $4.89. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Bioventus Inc. (Nasdaq: BVS) appoints Robert Claypoole as President and CEO, bringing over 20 years of medical device industry experience. The company reaffirms its full year financial guidance and expresses excitement for the future under Claypoole's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
-
Rhea-AI Summary
Bioventus Inc. (BVS) has secured a nationwide contract with Aetna™ Medicare Advantage plans, granting over 3 million members access to DUROLANE, a single-injection hyaluronic acid-based joint-fluid treatment for knee osteoarthritis (OA) pain, starting January 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
Rhea-AI Summary
Bioventus Inc. reported Q3 net sales of $120.8 million, down 6.1% year-over-year. The company's net loss from continuing operations was $8.8 million, compared to $101.0 million in the prior-year period. Adjusted EBITDA from continuing operations decreased 0.9%, and the loss per share of Class A common stock from continuing operations was $0.12. Pain Treatments revenue advanced 3.1%, and the company is raising its full-year earnings guidance. The company expects net sales of $498 million to $505 million and adjusted EBITDA of $84 million to $87 million for the twelve months ending December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
-
Rhea-AI Summary
Bioventus Inc. will report financial results for Q3 2023 on November 7, 2023. The conference call to discuss the results and provide a business update will be held at 8:30 a.m. Eastern Time. Dial 1-800-715-9871 or 1-646-307-1963 to participate. Webcast and materials will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences earnings
-
Rhea-AI Summary
Bioventus CFO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
Rhea-AI Summary
Bioventus CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
Bioventus Inc

Nasdaq:BVS

BVS Rankings

BVS Stock Data

289.64M
23.20M
11.14%
66.3%
0.99%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Durham

About BVS

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat